Mesoblast Limited (MESO) vs Xencor, Inc. (XNCR)
- Mesoblast Limited MESO 13.28 −4.80%
- Xencor, Inc. XNCR 22.95 −4.38%
Mesoblast Limited and Xencor, Inc. are both Biotechnology companies. Mesoblast Limited and Xencor, Inc. are of similar size ($1.8B and $1.8B). Mesoblast Limited grew revenue faster over the last twelve months: −26.5% against −28.6%. Xencor, Inc. has the higher net margin (−155.6% vs −1,091.7%) and the lower return on invested capital (−288.7% vs 0.00%). Across the 18 metrics below, Mesoblast Limited leads on 10 and Xencor, Inc. on 8.
Valuation
Profitability
| Metric | MESO | XNCR | Biotechnology median |
|---|---|---|---|
| Gross margin | (269.72%) | 100.00% | 65.16% |
| Operating margin | (826.28%) | (205.84%) | 0.00% |
| Net margin | (1,091.71%) | (155.59%) | 0.00% |
| Free cash flow margin | 0.00% | (198.42%) | 0.00% |
| Return on equity | 0.00% | (29.07%) | (56.36%) |
| Return on assets | 0.00% | (20.36%) | (48.04%) |
| Return on invested capital | 0.00% | (288.71%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack